Drug Combo Improves Recurrence-Free Survival After HCC Resection
The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.
Comunidad Autonoma De Cataluna United States Stephenl Chan National Cancer Center Singapore Chinese University Of Hong Kong American Association For Cancer Research
Source: medscape.com